Pay in 4 interest-free payments of $5.90 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Signal Transduct Target Ther 9:124
Although designed for cardiovascular safety, other safety aspects may also be assessed in CVOTs
All doses, protocols and outcomes discussed below are described strictly as reported in the peer-reviewed and preclinical literature
Five participants withdrew from the trial, including four in the placebo arm (two participants did not provide a reason for withdrawal, one participant did not have a weight loss response, and the remaining participant withdrew due to adverse event (AE) reasons)
The dual-receptor approach may create a more balanced physiological response that reduces acute GI disruption
US$ 22.62
US$ 28.82
US$ 27.47
US$ 25.98
US$ 24.26
US$ 28.42
